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•	 Janus kinase family consists of four signaling enzymes involved in cytokine signaling pathways.
•	 Modifications	of	JAK	enzymes	resulted	in	various	pathological	conditions.
•	 JAK2	modification	is	reported	in	several	types	of	cancers.	
•	 JAK modulators have been approved by FDA for treatment of several immunological and neoplastic 
disorders. 
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ABSTRACT
Janus Kinase (JAK) family is a group of four signaling enzymes composing of four distinct 
domains and involved in the intracellular pathways of cytokine downstream signaling. 
There are two kinase domains at C-terminal of protein, one of which is regulatory and the 
other has the main functionality in phosphorylation of target proteins. JAKs involve in the 
critical physiological processes, including immune response, growth, and differentiation. 
Mutations or malfunction of JAKs gene can result in pathological conditions like 
immuno-inflammatory	diseases	and	malignancies.	Targeting	of	JAK	enzymes	has	been	
considered	 as	 effective	 therapeutic	 approaches	 in	 immuno-inflammatory	disorders	 and	
different types of hematopoietic cancers or solid tumors. Rather than cytokines that are 
the natural modulators and the small chemical inhibitors developed as the therapeutic 
modulators of JAK enzymes, miRNAs can exert regulatory activity on JAKs. miRNAs 
are valuable biomarkers and regulatory elements of different pathophysiological 
conditions, particularly cancers. The relationships between JAK enzymes and miRNA 
are bi-directional, as the JAKs activity through JAK-STAT pathway as well as some other 
non-STAT pathways, control the expressions of various genes. These connections help 
scientists to design and develop novel therapeutic agents and predict the prognosis of 
disease following therapeutic regimens, based on these two critical components of cell 
biology.
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Introduction 
Intracellular signaling pathways emerge in various 
communications under different physiological or 
pathological conditions. The Janus kinase (JAK) family 
including JAK1, JAK2, JAK3 and TYK2 (tyrosine kinase 
2), involve in the intracellular signaling network through 
the cytokine receptors. Albeit, the exact mechanisms of 
the activation, regulation, and multi-functionality of these 
signaling enzymes have not been described completely, 
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and inhibit the oncogenic genes (Hayes et al., 2014; Lin 
and Gregory, 2015). 
One of the important pathways in cancer control 
is JAK-STAT (signal transducer of activators of 
transcription) that may interact with various miRNAs. 
The effect of different miRNAs on JAK pathways are 
discussed completely in a separate section. 
Janus kinase (JAK): structure/activity 
Structural analysis of JAK enzymes revealed that they 
consist of four domains with different functionalities, 
including: (i) an N-terminal FERM domain with direct 
interaction with cytokine receptors, (ii) a Src homology-2 
(SH2)-like domain whose exact function is not clear, 
(iii) a pseudokinase domain (JAK homology-2, JH2) 
whose kinase activity regulates the function of other 
kinase domain (JH1) and (iv) a C-terminal tyrosine 
kinase domain (JH1) which exert the main kinase 
activity in phosphorylation of target tyrosines. Generally, 
JAK enzymes contain two highly similar phosphate-
transferring domains with different and distinct activities, 
JH1 and JH2. The JH2 negatively regulates the kinase 
activity of the other domain named kinase domain (JH1) 
(Bandaranayake et al., 2012; Babon et al., 2014) (Fig. 1). 
Interaction of JAK enzymes with various receptors 
results in the JAK activation following the ligand binding 
to the receptors (cytokine-receptor interaction). The 
mechanism of JAK activation was studied and showed 
that the cytokine-induced receptor dimerization result in 
the phosphorylation of Tyr1007/Tyr1008 and activation of 
JAK catalytic domain. In addition, there are JAK activation 
mechanisms independent of receptor dimerization named 
as atypical or noncanonical activation. These mechanisms 
can activate through Gprotein-coupled receptors 
(GPCRs), oxidative stress and hypertonicity (Kurdi and 
Booz, 2009). 
JAK activity in healthy cells
JAK kinases have the physiological role in the cytokine 
until now.  JAK mutations could result in several human 
diseases,	 including	inflammatory	diseases,	haemopoietic	
malignancies,	and	 immunodeficiency	conditions	 (Babon	
et al., 2014). 
Different members of JAK family play various 
roles in diverse physio-pathological conditions. JAK3 
as the critical modulator of interleukins (ILs) including 
IL-2,	 4,	 7,	 9,	 15,	 and	 21,	 is	 specifically	 expressed	 on	
hematopoietic cells. Malfunction of JAK3 as the key 
component of lymphocyte development and survival, 
result	 in	severe	combined	immunodeficiency.	JAK1	and	
2 as well as TYK2 are universally expressed. Dysfunction 
of	TYK2	can	also	lead	to	primary	immunodeficiency	with	
increased IgE. The studies on mice exhibited the lethal 
effect of malfunction of JAK1 or JAK2. In contrast, JAK 
activity enhancement could result in leukemia, lymphoma, 
polycythemia	vera,	and	myelofibrosis	 (Yamaoka,	2016).	
Structural and functional aspects of JAK enzymes and 
the role of these enzymes in signaling pathways of cancer 
cells are illustrated in the distinct following sections.
MicroRNAs (miRNAs) are short non-coding double 
stranded RNAs produced by the RNA interference 
systems from a long single stranded premiRNA. Mature 
miRNAs can modulate the gene expression through 
the	 binding	 to	 the	 3′	 untranslated	 region	 (3′	 UTR)	 of	
mRNAs, and subsequently result in target degradation or 
prevention of target translation. The miRNAs’ activity is 
not completely selective and one miRNA can regulate the 
expression of various genes. In normal physiological state, 
some miRNAs regulate the gene expression according to 
the cell requirement and some others contribute to the 
cellular response such as cell growth and differentiation 
according to the external stimuli. In the pathological 
state,	 miRNA	 profiles	 of	 the	 cell	 and	 biological	 fluids	
are changed. Different miRNAs can exhibit complete 
contrary function in tumor pathology. First report about 
the miRNA deregulation in cancer was in 2002 that 
expressed	the	function	of	miRNA-15	and	miRNA-16	in	
chronic lymphocytic leukemia (CLL). Some miRNAs 
inhibit tumor suppressor genes and therefore, they are 
oncogenic, but the others have tumor suppressive function 
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signaling pathways and also involve in the signal 
transduction of colony-stimulating factors, and several 
stimulating hormones (Fig. 2). Among these kinases, 
JAK1 and JAK2 have a wide functionality in the host 
defense mechanisms, hematopoiesis, growth, and 
neural development and it was stated that the deletion 
of JAK1 or JAK2 could be lethal in mice. In addition, 
mutations of JAK3 and TYK2 could result in primary 
immunodeficiency	 diseases,	 such	 as	 severe	 combined	
immune	deficiency	(SCID)	(O’shea	et	al.,	2013).
It was previously stated that JAK3 selectively 
associates	with	gamma	chain	(γc)	and	no	other	cytokine	
receptors. As a result, its malfunction has a dominant role 
in	severe	combined	immunodeficiency.	In	addition,	wide	
distribution of JAK1 in different cells and its activity in 
signaling transduction of different cytokine receptors, 
particularly IFN related and also the receptors that use 
gp130	and	γc	had	also	been	stated	(O’Shea	et	al.,	2002).	
But	 now,	 it	 is	 confirmed	 that	 JAK1	 collaborates	 with	
JAK3	 in	 cytokine	 signaling	 through	 γc	 of	 receptors	 in	
the hematopoietic cells and its inactivation, regardless of 
the JAK3 status, could result in complete abolishment of 
STAT5 phosphorylation. Therefore, malfunction of JAK1 
can dominantly induce the immune-suppressive condition 
(Haan et al., 2011).   
JAK2 is widely expressed and associating with single 
chain	hormone	receptors,	the	common	β	chain	family,	and	
certain members of the class II receptor cytokine family 
(O’Shea et al., 2002). The function of JAK pathway in 
the proliferation and differentiation of neuronal precursor 
cells (NPCs) following the effect of growth factors was 
studied	and	the	results	confirmed	the	different	regulatory	
effect of JAK members. In this regard, JAK2 play an 
important role in the proliferation, maintenance, and 
proliferation start of NPCs, though JAK3 involves in 
the NPCs differentiation. JAK3 knock-down lead to the 
NPCs differentiation into neurons and oligodendrocytes, 
but not to astrocyte (Kim et al., 2010).
The relationship between cytokine signaling and JAK 
enzymes through JAK-STAT pathways have been highly 
investigated (Fig. 3).
JAK activity in cancerous cells
All of the JAK family members are the upstream kinases 
of STAT proteins that phosphorylate them and result in 
down-stream regulatory functions. Importance of JAK/
STAT pathway in various types of cancers had been 
comprehensively illustrated (Thomas et al., 2015). It 
was reported that the signaling pathway of JAK2/STAT3 
was involved in different types of cancer, including 
lung (Chuang et al., 2017), pancreatic cancer (Wang 
et al., 2014), breast (Watson and Hughes, 2014), and 
hepatocellular carcinoma (Mohan et al., 2014). Mutations 
of	JAK2	(most	frequently	V617F	mutation)	are	discovered	
in the myeloproliferative neoplasms, polycythemia vera, 
essential	 thrombocythemia,	 and	 primary	 myelofibrosis	
(O’shea et al., 2013).  
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Other members of JAK family can also involve in gene 
regulation and cancer development, such as JAK1in B cell 
lymphoma that could be the direct effect of JAK activity 
on the chromatin phosphorylation and subsequently, 
perturbs	the	gene	expression	(Rui	et	al.,	2016).		
It	was	also	confirmed	that	 targeting	of	JAK1/STAT3	
and blockage of this pathway effectively suppressed 
ovarian tumor progression (Wen et al., 2014). The 
therapeutic effect of JAK1 inhibitors in other cancer types 
such	 as	 lung	 (Wu	 et	 al.,	 2016),	 prostate	 (Handle	 et	 al.,	
2016),	gastric	(Song	et	al.,	2016),	colorectal	(Celtikci	et	
al., 2014), and breast (Kaushik et al., 2017) have been 
demonstrated.
Several types of JAK3 mutations were reported in 
lymphoma and leukemia. In a case of lung cancer, two types 
of	JAK3	mutation	were	identified	that	activate	the	JAK3.	
It promoted the programmed cell death-1 (PD-1) protein 
induction and according to the T-cell immunity inactivation 
resulted to the therapeutic resistancy and progression of 
cancer cells. It can be concluded that alteration of JAK3 
may	 have	 influence	 on	 the	 therapeutic	 activity	 of	 PD-
L1 inhibitors (Van Allen et al., 2015). Moreover, JAK3 
interaction with zeste homologue 2 (EZH2) involving in 
the epigenetic control of gene expression through histone 
methylation,	was	confirmed	and	it	was	shown	that	JAK3	
could phosphorylate EZH2 on tyrosine residue 244 and 
suppress EZH2 methyltransferase activity and as a result, 
the survival and proliferation of lymphoma cells promote. 
In contrast, JAK3 inhibition may suppress the survival 
and proliferation of lymphoma cells (Karantanos and 
Boussiotis,	2016).	In	cervical	cancer	cell	lines,	activation	
of JAK3 independent of JAK1 activity through IL-2 
receptor, could lead to the proliferation of cancer cells. 
That was different from the normal lymphocytes that 
IL-2 activation results in JAK1 phosphorylation and then 
JAK3 activation. Consequently, JAK3 inhibitor could be 
a promising treatment for cervical cancer (Valle-Mendiola 
et al., 2014).
JAK modulators 
The JAK-STAT pathway provides an important mechanism 
for controlling gene expression by extracellular factors. 
Along with four members of JAK family, seven types of 
STAT	proteins	have	been	 identified	 in	mammalians	 that	
each one is related to particular signaling pathway. JAK and 
STAT kinases may be independently activated and insert 
the down-stream functions on gene expression, instead 
of	 JAK/STAT	 pathway.	Malfunction	 or	 modification	 of	
JAK or STAT proteins can result in several disorders 
including	immunodeficiency	disorders	and	malignancies.	
Therefore, modulation of these pathways through JAK 
or STAT members can exhibit promising therapeutic 
activity in cancers (O’Shea et al., 2015). For example, 
MLS-2384	(6-bromoindirubin)	is	a	dual	JAK/Src	kinase	
inhibitor.	Related	study	confirmed	that	it	could	suppress	
growth of various human cancer cells, such as prostate, 
breast, skin, ovarian, lung, and liver. Inhibition of JAK 
and Src kinases also led to a dose-dependent inhibition 
of the phosphorylation of STAT3 (Liu et al., 2014). There 
are various types of small chemicals with JAK inhibitory 
function studied as potential therapeutic agent of cancers, 
autoimmune,	 and	 inflammatory	 disorders	 (Kettle	 et	 al.,	
2017; Kettle et al., 2017).  
Natural compounds have been evaluated as the JAK 
modulator, as well. In this regard, Brevilin A as an active 
compound extracted from medicinal herb, exhibited 
strong STAT3 signal inhibition and subsequent cell 
growth inhibition. Moreover, Brevilin A could also inhibit 
STAT1 signaling for cytokines induced phosphorylation 
of STAT3 and STAT1. Therefore, it could affect the 
expression of the target genes. In addition, Brevilin A 
could block the JAKs JH1domain and decrease the JAKs 
kinase activity (Chen et al., 2013). 
Figure 3. The association of JAK enzymes with different types of cytokines. Most of cytokines use two or more JAK members that shown in this 
schematic presentation (Murray, 2007).
Figure 4 
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It was stated that the highly conserved structure of the 
JAK ATP binding pockets can be an attractive target for the 
design and development of highly selective JAK inhibitors 
as pharmacological agents. In this regard, different types 
of chemical molecules have been introduced (Tan et al., 
2015; Leroy and Constantinescu, 2017).
In the design of anti-cancer therapeutic agents, it 
should be noted that the cooperation between JAK1 and 
JAK3 in T-cell transformation and incidence of different 
mutations in immune response promotion may lead to 
the resistance in cancer treatment with JAK inhibitors 
(Springuel et al., 2014).
Clinical applications of JAK modulators  
JAK agonists and antagonists, that respectively, activate 
or inhibit JAK phosphorylation activity, can result in 
different functionalities. Since the Janus kinases are 
the key enzymes in the signal transduction of multiple 
immunomodulatory cytokines, inhibition of their 
functions can result in immunosuppression; especially 
inhibitors of JAK3 can be good candidates for immune 
diseases. In addition, effective role of JAK enzymes in 
a wide range of malignancies led to the development of 
small chemical JAK inhibitors as the anticancer agents. 
Currently, several JAK inhibitors have been approved by 
FDA for clinical application (Aittomäki and Pesu, 2014).
Ruxolitinib	is	the	first	FDA-approved	inhibitor	of	JAK1/
JAK2 in Nov. 2011 marked for the clinical application 
in	 the	 treatment	 of	 myelofibrosis	 and	 also	 in	 2014,	 it	
was approved for Polycythemia Vera. The effectiveness 
study of Ruxolitinib in acute leukaemia, lymphoma, 
multiple myeloma, essential thrombocythaemia, prostate 
cancer, breast cancer, pancreatic cancer and rheumatoid 
arthritis are in progress in various phases of clinical trials 
(Aittomäki and Pesu, 2014). 
FDA also approved Tofacitinib in Nov. 2012, for 
the treatment of Rheumatoid Arthritis. It exhibited the 
inhibitory effect on JAK1 and JAK3 with low selectivity 
for JAK2. Several clinical trials are in progress for 
Tofacitinib evaluation in ulcerative colitis, psoriasis, renal 
transplantation, juvenile idiopathic arthritis, and dry eyes 
(Aittomäki and Pesu, 2014; Wu et al., 2015). 
The other JAK inhibitor approved in 2013 as a 
veterinary medication is Oclacitinib, for the treatment of 
pruritus associated with allergic dermatitis and also atopic 
dermatitis in dogs. Human clinical applications of JAK 
inhibitors in dermal disorders have been studied and JAK 
inhibitors	were	suggested	as	efficacious	 therapeutics	for	
alopecia areata, atopic dermatitis, psoriasis, and vitiligo 
(Damsky and King, 2017)
MicroRNAs as the JAK modulators
MicroRNAs (miRNAs) are a class of small, noncoding 
regulatory RNAs that negatively regulate target gene 
expression. They involve in a wide range of biological 
processes. The pattern of miRNAs in different cells 
and healthy or disease states are changed. Accordingly, 
miRNAs can be considered as valuable biomarker in 
diagnosis and treatment of various diseases (Lin and 
Gregory, 2015; Hao et al., 2017). The role of miRNAs 
Figure 4 
 
Figure 4. Schematic presentation of JAK-STAT pathway control on miRNAs (Witte and Muljo, 2014).
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Table 1. The relationships between miRNA and JAK enzymes in different diseases (several examples).





Atherosclerosis (Wang et al., 2017)
miR-23a JAK1
miR-23a mediated 
inactivation of the JAK1-
STAT3 pathway
Acute erythroid leukemia 
(AEL) (Su	et	al.,	2016)
miR-30c JAK1
mRNA levels of 
JAK1 were decreased 
when miR-30c was 
overexpressed






mRNA was inversely 
correlated with the miR-
448 level
pancreatic ductal 
adenocarcinoma (Yu et al., 2017)
miR-340 JAK1 miR-340 suppressed the JAK1/STAT3 pathway
Hepatocellular  
carcinoma (Yuan et al., 2017)
miR-133a JAK2
Overexpression of miR-
133a down regulated 
JAK2 mRNA
Heart failure (Chen et al., 2015)
miR-204 JAK2
miR-204 suppressed 
JAK2 and p-JAK2 
expression





Colorectal  cancer (Wei et al., 2017)
miR-135b JAK2 miR-135b-5p negatively targeted JAK2
Myocardial  ischemia/
reperfusion (Xie et al., 2017)
miR-133b and miR-135a JAK2
miR-133b and miR-135a 




miR-29b and miR-198 JAK3 miR-29b/miR-198 down-regulate JAK3 Renal carcinoma (Gigante	et	al.,	2016)
in severe disorders such as cancers is highly important 
and they regulate metastasis, cell proliferation and cell 
death.	JAK-STAT	pathways	can	influences	on	the	miRNA	
patterns. It was reported that miR-21, MiR-29a and miR-
29b-1 were induced through the JAK-STAT pathways and 
resulted in different incidents, as miR-21 is oncogene but 
MiR-29a and miR-29b-1 are tumor suppressors (Witte 
and Muljo, 2014).
MicroRNAs can also affect the JAK-STAT pathways 
through controlling the expression of JAK or STAT 
genes (Zhang et al., 2011; Wu et al., 2012; Yuan et al., 
2017). The mechanisms involved in miRNA activity on 
cell fate are highly varied; however, the key regulatory 
pathways of the cells such as JAK pathways, may be the 
main mechanism. miRNAs released from the cancerous 
cells could activate the JAK-STAT pathway especially 
STAT3 and result in the tumor progression (Lam et al., 
2013). The relationships between different miRNAs and 
JAK pathways, especially JAK-STAT pathways, have 
been studied in a wide range of physio-pathological states 
(several examples were presented in Table 1). 
Tumor	 suppressor	 miRNAs	 can	 have	 influence	 on	
the	IFN-γ	signaling	pathway;	including	anti-proliferative	
activity of miR-375 and miR-135a on gastric cancer 
and	miR-216a	 on	 pancreatic	 cancer	 that	 affected	 JAK2	
expression (Eichmüller et al., 2017). Some of miRNAs 
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controlled the JAK-STAT pathway indirectly, such as 
the impact of miR-142a on cytokine signaling and T cell 
differentiation. The miR-142a directly suppress SOCS1 
(suppressor of cytokine signaling 1) and as a result, 
upregulate the JAK2-STAT1 signaling in autoimmune 
diseases (Talebi et al., 2017). 
Regard to the miRNAs regulation of JAK pathways, 
it was stated that two miRNAs (the exact type of miRNA 
was	 not	 published)	 inhibited	 JAK2-mediated	 −1	 PRF	
(programmed	−1	ribosomal).	The	-1	PRF	is	a	regulatory	
pathway in human gene expression including the mRNAs 
encoding	JAK2	and	STAT1.	JAK2-mediated	−1	PRF	can	
likely emerge a regulatory feedback loop in cytokine 
signaling	(Dinman	et	al.,	2016).
Conclusion and Outlook 
One of the important signaling enzymes in cancer 
progression and prognosis, is Janus kinase family. Most 
of the down-stream effect of cytokines and growth 
hormones emerged through the JAK-STAT signaling 
pathways. Targeted inhibition of this central pathway 
could result in different genes regulation to treat patients 
with immunological disorders, hematologic cancers, 
and solid tumors. This pathway has impact on the gene 
expression through epigenetic regulation of transcription 
and translation, as the phosphorylation of key proteins 
can alter their activity. miRNAs are important biomarkers 
for different physio-pathological states and nowadays, 
considered as potential therapeutic agents in the treatment 
of various diseases, especially cancers. Bi-directional 
relationship between miRNAs and JAK signaling 
pathways	 has	 been	 confirmed	 as	 an	 interesting	 field	 of	
study in medicine and drug discovery. miRNAs control 
JAK expression and function as well as JAKs activity 
can	have	influence	on	miRNA	profile.	The	miRNA-JAK	
interactions and their impact on cell proliferation or 
apoptosis are extensively investigated in various types 
of cancers. Discovery of these interactions help scientists 
to	 introduce	 novel	 efficient	 therapeutic	 and	 diagnostic	
approaches. 
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